KF&Co. is a premier healthcare services strategic advisory firm transforming how high-growth organizations, payers, and private equity groups create lasting value in healthcare. KF&Co. stands apart through our distinctive approach: we invest directly alongside our partners, demonstrating an unwavering commitment to long-term success in models that deliver meaningful impact to patient care. Our strength lies in navigating the complex healthcare landscape through established relationships, data-driven insights, and innovative solutions that align the interests of all stakeholders in the care journey.

Sage Infusion is a patient focused full service specialty infusion provider for patients with autoimmune disorders and chronic infusion needs. Sage specializes eliminating avoidable cost for patients and risk-bearing providers who seek to partners with a forward thinking, value-based, infusion provider.

Wells Pharma of Houston is an emerging 503B platform focused on fully automating the manufacturing process for compounded sterile preparations.

Ascend Vision Partners supports premier ophthalmologists and optometrists who deliver exceptional eye care to patients. We provide business solutions for eye care professionals so they can focus on patient care. We offer custom business solutions for each of our partners so that your practice retains its authenticity and autonomy to meet the unique needs of your patients. We believe that when our business acumen connects with your clinical expertise we can drive eye care to the next level and deliver an exceptional patient experience.

Corporate Development executive responsible for the inorganic growth initiatives of MAXhealth, a portfolio Company of Arsenal Capital Partners. MAXhealth is a Florida based, primary care platform, responsible for the provision of high-quality care for its patient population.

Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is the largest community oncology practice on the west coast and Florida, and the nation’s leading value-based oncology services platform. TOI employs 75 physicians and mid-levels in 40 clinic locations, with over 500 total employees helping to deliver cutting edge, evidence-based cancer care to a population of over 1 million patients. TOI brings comprehensive, integrated cancer care into community settings, including Clinical Trials, Palliative Care programs, Stem Cell Transplants, Transfusions, and other care delivery models more traditionally associated with tertiary care settings.

CEO of Optum's 503B | 503A compounded sterile preparations business - responsible for the integration of the assets into Briova Infusion Solutions following the acquisition of Avella, by OptumRx.

As the Chief Operating Officer 503B | 503A for Avella, a $1.5 billion SRx platform, I am responsible for growing the revenue and profitability of the Company's 503B and 503A compounding platforms.

As the Executive Vice President of Corporate Development and Strategy for Avella, a $1.5 billion SRx platform, I am responsible for accelerating Avella's growth through long-term strategic planning and market development initiatives, partnerships, investments, acquisitions and post-merger integration. In addition, I drive organizational alignment on the positioning of Avella in the changing health care marketplace and identify new market opportunities and business models to further innovation and long-term growth.

QuadMed is a nationally recognized provider of employer sponsored onsite / near site direct primary care and wellness services. The model features a full continuum of high quality, patient-centered services, which are proven to decrease costs by increasing quality, accessibility and engagement. As the General Manager for QuadMed, I was responsible for accelerating QuadMed's growth through variety of initiatives including, acquisitions (Novia), investments in new technology (StatDoctors), joint ventures, and new employer relationships.

Exited December 2014 - Modernizing Medicine (https://www.modmed.com/) - Modernizing Medicine acquired by Warburg Pincus in 2017 (http://www.warburgpincus.com/investments/modernizing-medicine/)

As EVP I was responsible for all non-pharmacy operational, financial, business development and strategic activities required to drive the growth and acceptance of a unique, centralized, oncology compounding platform.

$4.0 billion distributor of specialty pharmaceuticals. Sold to McKesson in 2007.